NPCE
NeuroPace Inc

328
Mkt Cap
$469.64M
Volume
145,023.00
52W High
$18.98
52W Low
$7.56
PE Ratio
-18.71
NPCE Fundamentals
Price
$13.60
Prev Close
$14.10
Open
$14.32
50D MA
$10.97
Beta
1.11
Avg. Volume
122,740.65
EPS (Annual)
-$0.9318
P/B
25.34
Rev/Employee
$434,271.74
Loading...
Loading...
News
all
press releases
FY2025 EPS Estimates for NeuroPace Raised by HC Wainwright
NeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Equities researchers at HC Wainwright raised their FY2025 earnings estimates for shares of NeuroPace in a research note issued to investors on Thursday...
MarketBeat·11d ago
News Placeholder
More News
News Placeholder
NeuroPace (NPCE) Q3 2025 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·12d ago
News Placeholder
NeuroPace (NASDAQ:NPCE) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says
JPMorgan Chase & Co. lifted their target price on shares of NeuroPace from $16.00 to $18.00 and gave the company an "overweight" rating in a report on Wednesday...
MarketBeat·14d ago
News Placeholder
NeuroPace (NASDAQ:NPCE) Price Target Raised to $16.00 at Wells Fargo & Company
Wells Fargo & Company raised their price target on NeuroPace from $15.00 to $16.00 and gave the company an "overweight" rating in a research note on Wednesday...
MarketBeat·14d ago
News Placeholder
NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates
NeuroPace (NPCE) delivered earnings and revenue surprises of +45.00% and +11.38%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·16d ago
News Placeholder
NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the third quarter ended September 30...
Business Wire·16d ago
News Placeholder
NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of...
Business Wire·29d ago
News Placeholder
NeuroPace to Participate in Upcoming Healthcare Conferences
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in two healthcare...
Business Wire·3mo ago
News Placeholder
NeuroPace, Inc. (NPCE) Reports Q2 Loss, Beats Revenue Estimates
NeuroPace (NPCE) delivered earnings and revenue surprises of -8.33% and +0.75%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Stereotaxis Inc. (STXS) Reports Q2 Loss, Tops Revenue Estimates
Stereotaxis (STXS) delivered earnings and revenue surprises of +28.57% and +10.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago

Latest NPCE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.